Dupixent Lawsuit: Overview
Dupixent (dupilumab), made by Sanofi and Regeneron, is a biologic drug designed to suppress certain inflammatory pathways in the immune system, which are overactive in severe atopic dermatitis patients, asthma patients, and people with nasal polyps, eosinophilic esophagitis, and other type-2 inflammatory disorders.
Researchers are investigating whether Dupixent may affect the recognition, progression, or clinical presentation of certain T-cell lymphomas in some patients, particularly those whose underlying disease was initially diagnosed as atopic dermatitis.
Reports suggest some patients taking Dupixent later developed cutaneous T-cell lymphoma (CTCL) or were found to have hidden lymphomas that were undiagnosed before the drug was started, often because early signs mimic eczema.
Several published studies have reported elevated rates of cutaneous T-cell lymphoma and other mature T-cell lymphomas among certain groups of Dupixent users, prompting researchers to investigate whether the association reflects disease progression, delayed diagnosis, or a drug-related effect.
The theory is not yet conclusively proven, and many of the published cases have limitations (retrospective design, small numbers, lack of baseline biopsies), but the signal is raising alarms.
Defective drug lawyers argue that the Dupixent manufacturers failed to provide adequate warnings to patients and healthcare providers about these rare but aggressive form cancers.
In particular, when undiagnosed CTCL is present, using Dupixent may allow the disease to progress unchecked, possibly involving internal organs and more aggressive forms, including Sézary syndrome.
Important factors and developments on the links between Dupixent and CTCL
- Case reports and cohort studies have found patients with severe atopic dermatitis who started Dupixent later diagnosed with CTCL or other rare blood cancers.
- A retrospective matched cohort study published in Dermatologic Therapy reported a significantly elevated odds ratio for CTCL among Dupixent users compared to non-users, prompting further investigation into potential lymphoma risks associated with dupilumab use.
- Clinical reviews have identified instances where Dupixent appeared to “unmask” hidden lymphomas misdiagnosed as eczema, meaning symptoms looked like dermatitis but were actually early CTCL.
- Early-stage CTCL often presents with red patches, itching, scaling, and other symptoms that closely resemble eczema. Some researchers have reported cases in which patients initially treated for atopic dermatitis later underwent biopsies that revealed mycosis fungoides or Sézary syndrome.
- Some patients had worsening of their lymphoma once on Dupixent, especially blood involvement (e.g. Sézary syndrome) or progression of disease in internal organs after an initial skin-only presentation.
- In FAERS (FDA Adverse Event Reporting System) data and safety reports, there are hundreds of reports of lymphoma among Dupixent users, including a substantial number of CTCL cases.
- Systematic reviews of published case reports and observational studies have examined whether Dupixent may unmask previously undiagnosed CTCL or contribute to disease progression in certain patients.
Dupixent lawsuits allege Sanofi and Regeneron failed to adequately warn physicians and patients about reports of CTCL diagnoses, lymphoma progression, and other lymphoma-related safety concerns that emerged after the drug entered widespread clinical use.
For defenders, much of the dispute is whether there was pre-existing, undiagnosed CTCL (hidden lymphomas), misdiagnosis, or whether Dupixent actually causes these cancers rather than simply revealing them.
Because CTCL is a rare cancer, gathering reliable epidemiologic data is challenging, but the stakes are high for anyone who suffers from these outcomes.
CTCL Symptoms in Dupixent Users
One of the central issues in the Dupixent litigation involves the difficulty of distinguishing early-stage cutaneous T-cell lymphoma (CTCL) from chronic inflammatory skin conditions such as atopic dermatitis.
CTCL can develop gradually and often presents with symptoms that closely resemble eczema, leading some patients to receive treatment for dermatitis before a cancer diagnosis is considered.
Researchers have reported cases in which Dupixent patients were later diagnosed with mycosis fungoides, Sézary syndrome, or other forms of cutaneous lymphoma after initially being treated for presumed eczema.
Studies and case reports have examined whether dupilumab treatment may unmask previously undiagnosed CTCL or contribute to accelerated disease progression in certain patients, although the exact relationship remains under investigation.
In several published reports, treatment continued for months before additional testing revealed an underlying lymphoma diagnosis.
A recent population based cohort study found that patients with atopic dermatitis treated with dupilumab had an increased risk of receiving a CTCL diagnosis compared to matched patients who did not receive the medication.
Researchers have also analyzed the clinical characteristics of reported CTCL cases, including disease stage, biopsy findings, blood involvement, and treatment response patterns.
Symptoms described in published reports and clinical reviews include:
- Persistent red, discolored, or scaly skin patches
- Itching that continues despite eczema treatment
- Thickened skin plaques
- New or worsening skin lesions
- Tumor-like nodules or growths on the skin
- Enlarged lymph nodes
- Skin discoloration affecting larger areas of the body
- Recurrent skin infections
- Changes in previously stable dermatitis symptoms
Because CTCL and eczema share many clinical features, physicians often rely on repeated dermatologic evaluations and, in some cases, multiple biopsies to distinguish CTCL from chronic dermatitis.
Persistent symptoms, unusual skin lesions, treatment-resistant dermatitis, or worsening disease despite therapy may represent warning signs that additional testing is warranted.
Published reviews have noted that many reported CTCL cases were identified only after further diagnostic evaluation revealed an underlying lymphoma that had not previously been recognized.
New Study Reports Increased Lymphoma Risk in Asthma Patients Taking Dupixent
A 2025 population-based cohort study published in the European Respiratory Journal examined nearly 15,000 asthma patients treated with Dupixent and compared them to a matched group receiving standard inhaled asthma therapies.
Researchers found that dupilumab-treated patients had a higher rate of newly diagnosed lymphoma, with the strongest association observed among T-cell and natural killer (NK) cell lymphomas.
Unlike many earlier studies involving patients with atopic dermatitis, this research focused specifically on asthma patients, reducing concerns that undiagnosed cutaneous T-cell lymphoma (CTCL) had simply been mistaken for eczema before treatment began.
The study reported a 79% increased risk of lymphoma overall and a substantially higher risk of T-cell and NK-cell lymphomas among Dupixent users, with dupilumab compared to standard inhaled asthma therapies, researchers observed higher lymphoma rates among treated patients.
Researchers did not find a similar increase in other types of cancer, suggesting the findings may be specific to certain lymphoproliferative disorders.
The authors emphasized that the results do not establish that Dupixent causes lymphoma and called for additional research to better understand the relationship.
Nevertheless, the study has received significant attention because it expands lymphoma concerns beyond patients receiving Dupixent for skin conditions.
Plaintiffs in the Dupixent MDL have cited these findings as part of their argument that Sanofi and Regeneron should have provided stronger warnings regarding potential lymphoma risks associated with the drug.
What is Dupixent Used For?
Dupixent (dupilumab) is a monoclonal antibody that targets the interleukin-4 receptor alpha, blocking signaling of both IL-4 and IL-13, which are cytokines involved in many type 2 inflammatory conditions.
It has been approved by the FDA for multiple indications across skin, respiratory, and immune-mediated diseases.
Here are the current approved uses:
- Atopic Dermatitis (Eczema): For adults and children 6 months and older with moderate-to-severe atopic dermatitis not adequately controlled with topical therapies, or when topical treatments are not advisable.
- Asthma: As add-on maintenance treatment for people aged 6 years or older with moderate-to-severe asthma, especially an eosinophilic phenotype or those who are oral corticosteroid dependent.
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): For patients 12 and older whose disease is inadequately controlled.
- Eosinophilic Esophagitis (EoE): For patients aged 1 year and older.
- Prurigo Nodularis: For adult patients.
- Chronic Obstructive Pulmonary Disease (COPD): As an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
- Chronic Spontaneous Urticaria (CSU): For patients aged 12 years and older whose hives remain symptomatic despite H1 antihistamine treatment.
- Bullous Pemphigoid (BP): Recently approved (June 2025) for adult patients with bullous pemphigoid, a rare and relapsing skin blistering disease.
Dupixent cannot be used for relief of acute bronchospasm or status asthmaticus, and its use in certain indications is limited to specific patient populations (e.g. requiring the eosinophilic phenotype in asthma or COPD).
Because Dupixent is being used in more diseases, some of its latest approvals (CSU, BP, COPD) broaden the number of patients exposed, which is relevant in the litigation context.
Does the Dupixent Label Carry a Cancer Warning?
The FDA-approved Dupixent label currently does not contain a warning specifically addressing CTCL, mycosis fungoides, Sézary syndrome, or other lymphoma risks.
The label discusses a number of other safety concerns, including hypersensitivity reactions, conjunctivitis, keratitis, eosinophilic conditions, and parasitic infections, but it does not include a lymphoma-specific warning.
Published studies, case reports, adverse event data, and ongoing litigation have raised questions about a possible association between Dupixent and certain T-cell lymphomas, particularly CTCL.
The FDA has identified CTCL as a potential safety signal and has evaluated whether additional regulatory action or labeling changes may be appropriate. As of mid-2026, however, no CTCL-related warning has been added to the U.S. prescribing information.
The absence of a lymphoma warning has become a central issue in the federal Dupixent multidistrict litigation, where plaintiffs allege Sanofi and Regeneron failed to adequately warn doctors, dermatologists, and patients about emerging lymphoma-related safety concerns.
Do You Qualify for the Dupixent Lawsuit?
Eligibility for the Dupixent lawsuit depends on whether a patient developed lymphoma or another serious complication after using the medication.
Attorneys review medical records and a detailed treatment history to determine if there is a connection between Dupixent use and a later cancer diagnosis.
Many claims involve individuals who were prescribed dupilumab for eczema, asthma, or related inflammatory conditions before later receiving a CTCL diagnosis.
TorHoerman Law offers a free case evaluation to help patients understand whether they may have a valid claim.
These lawsuits are centered on patient safety, arguing that manufacturers failed to disclose the risks and left patients vulnerable.
Those affected may be entitled to seek compensation for medical bills, lost wages, pain and suffering, and other damages.
Families of patients who developed severe or fatal complications may also qualify to pursue legal action.
Speaking with an experienced lawyer can help determine whether your circumstances meet the criteria for a Dupixent lawsuit.
Gathering Evidence for the Dupixent Lawsuit
Building a strong Dupixent lawsuit requires thorough documentation that clearly links the drug to a patient’s injuries.
Lawyers rely on detailed records that show when Dupixent was prescribed, how long it was taken, and what health changes occurred during and after treatment.
Evidence is especially important in cases where patients later developed lymphoma or other serious complications that may have been overlooked or misdiagnosed.
The more complete the documentation, the stronger the case for holding the manufacturers accountable.
Evidence that may support a Dupixent lawsuit includes:
- Complete medical records, including diagnoses and pathology reports
- A full treatment history, with dates and duration of Dupixent use
- Biopsy results showing CTCL or another lymphoma diagnosis
- Documentation of worsening symptoms or unexplained skin changes
- Records of visits with dermatologists, oncologists, or other specialists
- Pharmacy records or prescription logs confirming Dupixent prescriptions
- Imaging or laboratory results indicating spread to lymph nodes or internal organs
- Correspondence between patients and healthcare providers about ongoing concerns
Damages in Dupixent Lymphoma Lawsuit Claims
When a patient suffers harm from a prescription drug, the legal system allows them to pursue compensation for both economic and non-economic losses.
In Dupixent lymphoma cases, damages are meant to address the wide-ranging impact of a cancer diagnosis on a patient’s health, livelihood, and family life.
These claims focus on the costs of medical care, the income lost due to illness, and the personal toll of living with a rare and aggressive disease.
By seeking damages, patients and families can hold drug manufacturers accountable for the consequences of inadequate warnings and undisclosed risks.
Potential damages in a Dupixent lawsuit may include:
- Past and future medical expenses related to lymphoma treatment
- Lost wages and diminished earning capacity
- Pain and suffering caused by the disease and its treatment
- Emotional distress and reduced quality of life
- Loss of consortium or companionship for family members
- Funeral and burial expenses that may be sought through a Dupixent wrongful death lawsuit when lymphoma-related complications result in death.
- Punitive damages, if the court finds reckless conduct by the manufacturers
